Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

141 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A multi-center, single-arm, phase Ib study of pembrolizumab (MK-3475) in combination with chemotherapy for patients with advanced colorectal cancer: HCRN GI14-186.
Herting CJ, Farren MR, Tong Y, Liu Z, O'Neil B, Bekaii-Saab T, Noonan A, McQuinn C, Mace TA, Shaib W, Wu C, El-Rayes BF, Shahda S, Lesinski GB. Herting CJ, et al. Among authors: lesinski gb. Cancer Immunol Immunother. 2021 Nov;70(11):3337-3348. doi: 10.1007/s00262-021-02986-5. Epub 2021 Jun 23. Cancer Immunol Immunother. 2021. PMID: 34160684 Free PMC article. Clinical Trial.
Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF, Lesinski GB, Anghelina M, Parihar R, Valentino D, Liu J, Nadella P, Sundaram P, Young DC, Sznol M, Walker MJ, Carson WE 3rd. Eisenbeis CF, et al. Among authors: lesinski gb. J Clin Oncol. 2005 Dec 1;23(34):8835-44. doi: 10.1200/JCO.2005.02.1691. J Clin Oncol. 2005. PMID: 16314644 Clinical Trial.
Activation of extracellular signaling regulated kinase in natural killer cells and monocytes following IL-2 stimulation in vitro and in patients undergoing IL-2 immunotherapy: analysis via dual parameter flow-cytometric assay.
Kondadasula SV, Varker KA, Lesinski GB, Benson DM Jr, Lehman A, Olencki T, Monk JP, Kendra K, Carson WE 3rd. Kondadasula SV, et al. Among authors: lesinski gb. Cancer Immunol Immunother. 2008 Aug;57(8):1137-49. doi: 10.1007/s00262-007-0444-7. Epub 2008 Jan 10. Cancer Immunol Immunother. 2008. PMID: 18193422 Free PMC article.
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumors.
Ramaswamy B, Bekaii-Saab T, Schaaf LJ, Lesinski GB, Lucas DM, Young DC, Ruppert AS, Byrd JC, Culler K, Wilkins D, Wright JJ, Grever MR, Shapiro CL. Ramaswamy B, et al. Among authors: lesinski gb. Cancer Chemother Pharmacol. 2010 May;66(1):151-8. doi: 10.1007/s00280-009-1145-z. Epub 2009 Sep 23. Cancer Chemother Pharmacol. 2010. PMID: 19774377 Free PMC article. Clinical Trial.
Distinct myeloid suppressor cell subsets correlate with plasma IL-6 and IL-10 and reduced interferon-alpha signaling in CD4⁺ T cells from patients with GI malignancy.
Mundy-Bosse BL, Young GS, Bauer T, Binkley E, Bloomston M, Bill MA, Bekaii-Saab T, Carson WE 3rd, Lesinski GB. Mundy-Bosse BL, et al. Among authors: lesinski gb. Cancer Immunol Immunother. 2011 Sep;60(9):1269-79. doi: 10.1007/s00262-011-1029-z. Epub 2011 May 21. Cancer Immunol Immunother. 2011. PMID: 21604071 Free PMC article.
141 results